TG Therapeutics
a commercial stage biopharmaceutical company
TGTX Nasdaq
ISIN US88322Q1085 SEC CIK 1001316 LEI 529900X21UKABN9NJ529
Follow TG Therapeutics
Weekly email: filings, results
Revenue, last quarter
$259.9M
+60.7% vs same quarter last year
Net income
$55.5M
−85.8% vs same quarter last year
EPS, diluted
$0.35
−85.6% vs same quarter last year
Operating cash flow
$45.2M
+295.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $616.3M | $447.2M |
| FY24 | $329M | $23.4M |
| FY23 | $233.7M | $12.7M |
| FY22 | $2.8M | −$198.3M |
| FY21 | $6.7M | −$348.1M |
| FY20 | $152K | −$279.4M |
| FY19 | $152K | −$172.9M |
| FY18 | $152K | −$173.5M |
| FY17 | $152K | −$118.5M |
| FY16 | $152K | −$78.3M |
| FY15 | - | −$62.9M |
| FY14 | - | −$55.8M |
| FY13 | - | −$20.5M |
| FY12 | - | −$18.1M |
| FY11 | - | −$853.1K |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 83.7% | 20% | 72.6% |
| FY24 | 88.3% | 12.7% | 7.1% |
| FY23 | 94% | 8.8% | 5.4% |
| FY22 | 90.5% | −7839% | −7120.3% |
| FY21 | 88.2% | −5154.3% | −5204.1% |
| FY20 | - | −179996.1% | −183803.3% |
| FY19 | - | −111220.4% | −113730.9% |
| FY18 | - | −114736.8% | −114132.9% |
| FY17 | - | −78100% | −77944.7% |
| FY16 | - | −51953.3% | −51482.2% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$25M |
| FY24 | −$40.6M |
| FY23 | −$31.4M |
| FY22 | −$176.2M |
| FY21 | −$296M |
| FY20 | −$214.9M |
| FY19 | −$132.9M |
| FY18 | −$129M |
| FY17 | −$93.8M |
| FY16 | −$61.9M |
| FY15 | −$44.7M |
| FY14 | −$35.1M |
| FY13 | −$10.7M |
| FY12 | −$5.2M |
| FY11 | −$86.6K |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | $0 |
| FY14 | $0 |
| FY13 | $149.8K |
| FY12 | $84.5K |
| FY11 | - |
- TG Therapeutics
- Healthcare median
Show the numbers
| Year | TG Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 72.6% | −30.6% |
| FY24 | 7.1% | −47% |
| FY23 | 5.4% | −58% |
| FY22 | −7120.3% | −80.4% |
| FY21 | −5204.1% | −71.9% |
| FY20 | −183803.3% | −62.2% |
| FY19 | −113730.9% | −46.3% |
| FY18 | −114132.9% | −49.6% |
| FY17 | −77944.7% | −45.9% |
| FY16 | −51482.2% | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |